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A B S T R A C T
Background
Short term high dose corticosteroid treatment improves symptoms and short term disability after an acute exacerbation of multiple
sclerosis (MS) but it is unknown whether its long-term use can reduce the accumulation of disability.
Objectives
To determine the efficacy and safety of long-term corticosteroid use in MS.
Search methods
We searched The Cochrane MS Group Trials Register (February 2007),the Cochrane Central Register of Controlled Trials (The
Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007) and EMBASE (1980 to February 2007). In an effort to identify
further published, unpublished and ongoing trials we searched reference lists and contacted trial authors and one pharmaceutical
company.
Selection criteria
We considered controlled, randomised trials (RCTs), with or without blinding, of long term treatment (i.e. longer than 6 months) of
any type of corticosteroid in MS, irrespective of disease course.
Data collection and analysis
Reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information.
Main results
Three trials, all classified at high risk of bias, contributed to this review (Miller 1961; BPSM 1995; Zivadinov 2001) resulting in a
total of 183 participants (91 treated). Corticosteroid therapy did not reduce the risk of being worse at the end of follow-up (odds ratio
[OR] 0.51, 95% confidence interval [CI] 0.26 to 1.02) but there was a substantial heterogeneity between studies (I2: 78.4%). I. v.
periodic high dose methylprednisolone (MP) was associated with a significant reduction in the risk of disability progression at 5 years
in relapsing-remitting (RR) MS (OR 0.26, 95% CI 0.10 to 0.66), while oral continuous low dose prednisolone was not associated
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with any risk reduction in disability progression at 18 months (OR 1.23, 95% CI 0.43 to 3.56). Risk of experiencing at least one
exacerbation at end of follow-up was not significantly reduced with corticosteroid treatment (OR 0.36; 95% CI 0.10 to 1.25).
Only one study recorded adverse events: in one patient i. v. MP was discontinued after the fourth pulse when he developed acute
glomerulonephritis; a second patient was removed from the study after the fifth i. v. MP pulse because of severe osteoporosis.
Authors’ conclusions
There is no enough evidence that long-term corticosteroid treatment delays progression of long term disability in patients with MS.
Since one study at high risk of bias showed that the administration of pulsed high dose i. v. MP is associated with a significant reduction
in the risk of long term disability progression in patients with RRMS, an adequately powered, high quality RCT is needed to investigate
this finding.
P L A I N L A N G U A G E S U M M A R Y
The long-term use of anti-inflammatory corticosteroids for treating multiple sclerosis
Multiple sclerosis is an inflammatory disease affecting the brain and spinal cord. It results in episodes of neurological deficit which recover
(relapses) as well as accumulation of sustained disability with the passage of time. Corticosteroids are potent anti-inflammatory drugs.
It is postulated that long-term use of steroids may reduce the accumulation of disability. The reviewers found three studies addressing
this issue. A meta-analysis showed a trend towards a beneficial effect of long-term corticosteroids on accumulation of disability; however
only two small studies contributed to this result. It was not possible to reliably comment on the effect of long-term corticosteroids on
the frequency of relapses. Side effects were poorly documented. Therefore rigorous randomised controlled trials of this treatment are
warranted.
B A C K G R O U N D
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system whose aetiology is still un-
known. Treatment is based on the assumption that autoimmunity
plays a major role in the pathogenesis of disease (Compston 2002;
Rizvi 2004a; Rizvi 2004b; Frohman 2005).
Corticosteroids inhibit lymphocyte proliferation and the synthe-
sis of most known proinflammatory cytokines and cell surface
molecules required for immune function with a mechanism that
involves a specific corticosteroid receptor (Sloka 2005). Because of
their potent anti-inflammatory effects, corticosteroids have been
used to treatMS patients since the 1950s and today are considered
the standard treatment for acute exacerbations (Compston 2002;
Rizvi 2004b; Frohman 2005). However, corticosteroids, being im-
munosuppressive drugs, might prevent or delay the occurrence of
future episodes of inflammatory demyelination (Gold 2001).
A previous Cochrane review showed that a short term high dose
intravenous methylprednisolone (i. v. MP) course within 8 weeks
of acute exacerbation of MS, improved symptoms and short term
disability without significant side effects but data were insufficient
to estimate the effect on prevention of new exacerbations and
reduction of long term disability (Filippini 2000). In the present
review we wanted to consider long term corticosteroid treatment
to specifically prevent disease progression rather than to treat acute
exacerbations.
The idea that corticosteroids might prevent new exacerbations, re-
duce long term disability, and therefore modify the natural history
of MS, comes from several observations:
• the initial results of the Optic Neuritis Treatment Trial
suggested that treatment of a first episode of optic neuritis with a
single course of i. v. MP followed by a tapering course of oral
prednisone, reduced the 2 year rate of development of clinically
definite MS (Beck 1993), although this effect was lost on further
follow-up extending to 4 years (Beck 1995);
• a phase II randomised controlled trial (RCT) in relapsing-
remitting (RR) MS comparing the efficacy of repeated pulsed i.
v. MP with i. v. MP at the same dosage regimen but administered
only for relapses, showed that pulsed i. v. MP slowed the
development of destructive lesions (T1 black holes), the rate of
whole-brain atrophy progression and the development of
sustained physical disability (Zivadinov 2001);
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• another phase II RCT of bimonthly i. v. MP pulses in
patients with secondary progressive (SP) MS showed a beneficial
effect on time to onset of sustained progression of disability with
the high-dose regimen (Goodkin 1998a);
• one non randomised trial with historical controls suggested
that patients with MS treated with high dose i. v. corticosteroids
during six months post-partum might reduce the childbirth-
associated risk of acute exacerbation (de Seze 2004);
• some studies indicated that pulsed i. v. MP produced a
rapid and dose dependent reduction in gadolinium enhancement
on cerebral MRI that lasted for up to 6 months ( Gasperini
1997; Goodkin 1998b; Smith 1993; Barkhof 1994).
In a systematic review (Brusaferri 2000) that included around
500 randomised patients comparing the effects of adrenocorti-
cotrophic hormone (ACTH), prednisolone or MP (with or with-
out azathioprine) versus placebo, no significant effect on long-
term disability and relapse prevention was noted. However this
meta-analysis included studies in which these agents were given
for as little as 5-30 days. The review also reported the occurrence
of both minor and major side effects, the latter including severe
Cushing’s syndrome, hypertension, herpes simplex, herpes zoster,
severe ankle oedema, femoral fracture and gastrointestinal bleed-
ing, but these occurred with ACTH or an azathioprine/methyl-
prednisolone combination (Brusaferri 2000).
Pulsed regimens of administration have renewed interest in corti-
costeroids as they are reported to be well-tolerated and safe, with
only minor and dose-related side effects, such as insomnia, tran-
sient mood disorders, acneiform-rash, heartburn, headache and
myalgias (Pozzilli 2004). The rationale for repeated pulsed admin-
istration is based on the hypothesis that these drugs may have a
long-lasting immunosuppressive effect, as indicated by the above
mentioned studies, and that MS may be a restless, progressive dis-
ease even when, as in the RR form, the clinical course between
two exacerbations is stable (Stone 1995).
Thus, a systematic review of RCT to gather all data available to
date on long term use of corticosteroids appeared worthwhile.
O B J E C T I V E S
The objective of this review was to determine whether long term
treatment of MS patients with corticosteroids:
1) prevents or significantly delays disability progression at long
term follow-up;
2) reduces the risk of exacerbations, increasing the proportion of
relapse-free patients during follow-up;
3) is well tolerated and safe.
We selected progression of disease rather than the occurrence of
exacerbations as the primary outcome measure, both because the
frequency of exacerbations does not necessarily correlate with clin-
ical evidence of disease progression (Confavreux 2000), a more
meaningful parameter than the occurrence of symptoms and signs
that can remit, and because we also wanted to consider progressive
forms of the disease.
We also wanted to evaluate the effect of different doses, drugs,
routes of administration, regimens (i.e. pulsed or continuous),
length of treatment and whether the effect of treatment was dif-
ferent according to types of disease (relapsing/remitting, relaps-
ing/progressive [RP], secondary progressive or primary progressive
[PP]).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to consider all apparently unconfounded RCTs, with
or without blinding, of long term treatment with corticosteroids
in MS.
Types of participants
Patients with definite MS according to clinical and paraclinical
diagnostic criteria (Poser 1983; McDonald 2001; Polman 2005)
irrespective of their disease course (RR, RP, SP or PP). Studies
describing only clinical criteria were accepted as well (McDonald
1977).
Types of interventions
Active treatment: long term courses (i.e. longer than 6 months) of
any type of corticosteroid, continuous or intermittent, provided
that they were not started for relapses (i.e. started more than 2
months after a relapse), whatever the administration route and
dosage.
Control: placebo or no treatment. Short courses (i.e. maximum
21 days of duration) of corticosteroids were permitted, provided
they were administered for relapses.
Types of outcome measures
Primary outcomes
Efficacy
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We studied the following outcome measures in either treatment
group at 1 and 2 years and at the end of the scheduled follow-up
period:
Primary outcome
1. Patients who progressed. Whenever unspecified, progression
was defined as a persistent worsening of at least one point in EDSS
(Kurtzke 1983), recorded whilst not in relapse. However, other
definitions of progression were accepted, including a persistent
half-point increase starting from EDSS score 5.5, as is often re-
ported in the literature.
Safety
Safety outcome was assessed among primary endpoints by unique
measures incorporating all events occurring throughout the trials:
1. Number of patients with severe side effects. If not otherwise
specified, side effects were defined as severe when leading to one of
the following: death, hospitalisation, treatment discontinuation.
2. Extraction of any available information about safety in both
corticosteroid and control groups.
Secondary outcomes
2. Patients experiencing at least one exacerbation, which was de-
fined as the acute or subacute appearance/reappearance of neuro-
logical signs and symptoms for at least 24 hours, in the absence of
fever or infection.
3. Relapse free survival, if available.
Search methods for identification of studies
One reviewer (FB) provided references pertinent to this review
already retrieved in the course of two previous systematic reviews
on corticosteroids for multiple sclerosis which he had co-authored
(Brusaferri 2000; Filippini 2000). The same search strategy was
used in this review to update searches.
Electronic searches
The search strategy we used was drawn from the one developed
by the Multiple Sclerosis Group.
Relevant trials were identified searching the following sources:
1. The Cochrane MS Group Trials Register (February 2007)
2. The Cochrane Central Register of Controlled Trials (The
Cochrane Library 2007, Issue 1)(Appendix 1)
3. MEDLINE (January 1998 - February 2007)(Appendix 2)
4. EMBASE (1998 - February 2007)(Appendix 3)
Papers in any languagewere accepted provided theymet the criteria
specified above.
Searching other resources
4. Reference lists of studies on corticosteroid treatment for MS
5. Abstracts of neurological and multiple sclerosis congresses and
symposia, conference proceedings, dissertations and other forms
of reports where trials relevant to the review are likely to have been
published
6. We searched for unpublished studies by contacting researchers
who were known to be involved in this field
7. We contacted Pfizer Inc, who had acquired Upjohn, a company
which was known to have an interest in the use of steroids in MS,
in order to identify any unpublished data.
Data collection and analysis
Selection of studies
The contact reviewer (AC) divided the search results between co-
reviewers (SB, FB, IG, CS and AP) who decided separately which
articles to retrieve. Abstracts of references with titles of interest
were examined to determine relevance. When the abstract sug-
gested relevance, or relevance was unclear from the abstract, or
where no abstract was available, a copy of the article was obtained.
Copies of articles identified in reference lists of papers related to the
use of corticosteroid treatment in MS were also obtained. Trained
reviewers (AC and FB) verified that the papers thus selected ad-
hered to the inclusion criteria. AC and FB were not blinded to the
names of the authors, their institutions, the journal, or the journal
publisher. Disagreements were resolved by discussion between the
two reviewers.
All studies meeting the inclusion criteria were summarized in the
table Characteristics of Included Studies.
Assessment of methodological quality
Each reviewer (AC, SB, FB, IG, AP and CS) separately extracted
information, for each included trial, regarding the method of ran-
domisation, blinding of outcome evaluators, and whether all the
randomised patients were accounted for in the analysis. One re-
viewer (AC) contacted the authors of the trials if the above infor-
mation was not available in the published reports. In the case of an
unpublished study (BPSM 1995) this information was extracted
from the protocol approved by local Ethics Committee in 1995.
Since two reviewers (AC and SB) had a leading role in such study,
they did not participate to the assessment of methodological qual-
ity. Reviewers assessed the quality of the trials independently and
were asked to fill in a form shown in Table 1 that was then sent to
the contact reviewer (AC). Concealment of allocation (telephon-
ing to a central office, first entering the data into a computer,
the pharmacy, using identical numbered containers, or sequential,
sealed, opaque envelopes), blinding in outcome evaluation and
intention-to-treat analysis were evaluated and graded as present,
absent or unclear. The included studies were categorised into one
of three quality categories (protection against bias), based on those
described in the Cochrane Handbook for Systematic Reviews of
Interventions 4.2.6 (section 6.7.1): A (low risk of bias, all of the
criteria present), B (moderate risk of bias, one or more criteria un-
clear), C (high risk of bias, one or more criteria absent) (Higgins
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2005). We planned to summarise the interobserver agreement in
the overall quality score using the weighted kappa statistic.
Data extraction
All the reviewers (AC, SB, FB, IG, AP and CS) independently
extracted data for outcome and safety assessments according to
measures defined in the ’Types of outcome measures’ section, fill-
ing a form shown in Table 2. Forms were then sent to the contact
reviewer (AC) who summarized the data. The same forms were
used to ask original authors for unpublished data.
We planned to use intention-to-treat analysis, extracting the num-
ber of patients originally allocated to each treatment group irre-
spective of compliance. When numbers extracted by two or more
reviewers varied, differences were resolved by discussion.
Data analysis
The efficacy analyses were based on the results of the individual tri-
als for disability at one year or more after treatment initiation and
the safety analyses on the results for severe side effects. The anal-
yses on secondary outcomes and on minor side effects were used
to support the data on primary outcomes. A weighted estimate of
the treatment effects across trials (odds ratio) was calculated using
a fixed effect model. For interpreting the results, 95% confidence
intervals were used. Heterogeneity across studies was quantified
using I2, i.e. by describing the percentage of the variability in the
effect estimates that is due to heterogeneity rather than sampling
error. A value greater than 50% was considered substantial hetero-
geneity. (Higgins 2002)
Sensitivity analyses
If patients were excluded or lost to follow up after randomisation,
further information was sought by correspondence with the trial-
ists. If the data about these patients remained unavailable, a worst-
case scenario analysis for the outcome of “disability progression”
was undertaken to ensure significance of the results. In this anal-
ysis, it was assumed that those patients who were lost to follow
up in the treatment group had the worst outcome while those
patients who were lost to follow up in the control group had the
best outcome. We planned to make a definite conclusion about
the treatment effectiveness if the effects of primary and worst-case
meta-analyses were in the same direction and magnitude.
Subgroup analyses
If substantial heterogeneity was found on efficacy analysis, we
planned to explore this heterogeneity using the following subgroup
analyses:
(1) comparison of trials with quality A with trials with quality B
or C;
(2) comparison of the efficacy of treatment in patients treated
within one year versus those treated after one year of MS onset;
(3) comparison of the effect of different doses, drugs, routes of ad-
ministration, regimens (i.e. intermittent or continuous) and length
of treatment;
(4) comparison of the efficacy of treatment in RR, RP, SP or PP
patients
We planned to use the overlap of the confidence intervals of the
summary estimates in the groups of comparison (lack of overlap
between confidence intervals indicating statistical significance).
R E S U L T S
Description of studies
We identified 2270 articles (previous systematic reviews 111;
CENTRAL 170; MEDLINE 1741; EMBASE 242 ; hand search-
ing 4; unpublished 2; drug manufacturers zero).
Ten possible RCTs involving long-term administration of steroids
in MS were selected by reviewers on the basis of inclusion criteria
after reading the abstracts. We excluded seven studies after reading
the full published papers: one study was a dose-comparison trial
of i. v. MP without a control group (Goodkin 1998a), two studies
usedMRIparameters as outcomemeasures (Pato-Pato 2003;Then
Bergh 2006), one study was a case series with a historical control
group (de Seze 2004), two studies were uncontrolled case series
(Beretta 1997; Pirko 2004); one study was a comparison with
vitamin B12 (Tourtellotte 1965). (See table of excluded studies).
In total three trials contributed to this review: Miller 1961, BPSM
1995 and Zivadinov 2001.
Data availability
One study was unpublished (BPSM 1995) because it was prema-
turely interrupted for organisational problems and lack of fund-
ing. This study’s data were made available by one of the reviewers
(SB) and checked by a second reviewer (CS). The other two RCTs
were published as full papers. However, since the exact number of
patients with disability worsening and experiencing exacerbations
during follow-up could not be extracted from the Zivadinov 2001
paper, this information was obtained by contacting the authors.
Type of interventions and patients
Both the BPSM 1995 and Zivadinov 2001 studies used pulsed
high dose i. v. MP in RRMS whilst the study byMiller 1961 used
continuous oral prednisolone in patientswith “slowly progressive”,
“fluctuant” and “rapidly progressive” MS (diagnostic criteria were
not given). Patients in the control group were allowed to be treated
with corticosteroids in case of exacerbation in two studies (BPSM
1995; Zivadinov 2001) but in one of them (BPSM) the occurrence
of a relapse automatically ended the study for individual patients
(see “Outcomes definition” in this paragraph for further details).
Treatment duration was 18 months in the Miller 1961 study, 5
years in the Zivadinov 2001 study and two years or until the first
relapse in the BPSM 1995 (see table of included studies).
Baseline characteristics
Equivalence between the treatment and control group in the base-
line participants’ characteristics was present in the three selected
RCTs.
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Outcomes definition
- The Miller 1961study used different clinical outcome measures
(see table of characteristics of included studies). To extract data
on progression of disability we used the reported number of pa-
tients who “deteriorated” at the “patients’ own assessment” at 18
month (that outcome was divided in “improved”, “deteriorated”
and “remained unchanged” in the paper), making due allowance
for the potential biases involved in such definition. “Acute exac-
erbation” was not defined and data was reported for individual
relapses rather than for the number of patients experiencing at
least one exacerbation. Since we could not get further clarification
about acute relapses in the Miller study we could not consider
such study for analysis on prevention of new exacerbations.
- In theBPSM1995 study, progressionof disabilitywas definedbut
patients were not followed-up after the first exacerbation, contrary
to what was planned. Since patients not experiencing a relapse in
the two years of the study were just 2, we did not have any data on
long-term disability progression for the majority of the patients.
- The Zivadinov 2001 study defined progression of disability as
at least a 1.0-point worsening from baseline for patients who en-
tered at or below an EDSS score of 5.0 or a 0.5-point worsening
from baseline for patients who entered at an EDSS score of 5.5.
Worsening was required to persist for at least two consecutive 4-
month visits during the first 3 years of the study or at least two
consecutive 6-month visits during the fourth and fifth years of the
study. Relapses were defined as the appearance or reappearance
of one or more symptoms, attributable to MS, accompanied by
objective deterioration on neurologic examination, lasting at least
24 hours, in the absence of fever, preceded by neurologic stability
for at least 30 days and in the absence of steroid withdrawal within
60 days of the new event.
Risk of bias in included studies
Randomisation and concealment allocation
Themethod of randomisationwas centralised, providing adequate
concealment of allocation in two trials (BPSM 1995; Zivadinov
2001): in the BPSM 1995 study randomisation and allocation
were generated by computer by personnel not involved in patients
management and in the Zivadinov 2001 study this was done by
a statistician “who had no contact with the study subjects”. In
the Miller 1961 the method of randomisation was classified as
“unclear” by all the reviewers independently, since the method of
randomisation was not described.
Blinding
The BPSM 1995 and Miller 1961studies were double blinded.
During the Zivadinov 2001 study blindness to treatment of pa-
tients and clinical examiners was not warranted (although partici-
pants did not know the allocation group into which they will have
been allocated at the randomisation step); radiologists conducting
image analysis were blinded.
Intention-to-treat analysis, excluded and losses to follow-up
An intention-to-treat analysis was impossible for all the three tri-
als. In the BPSM 1995 study the intention to treat analysis was
planned but not performed and there were 10 patients (7 treated)
lost to follow-up (28% overall). Moreover, patients experiencing
an exacerbation were not followed up although a two year follow-
up was planned. In the Zivadinov 2001 and Miller 1961 trials a
total of 11 participants (7% overall) were excluded after randomi-
sation or lost to follow-up (see details in table of included studies).
No information was available on the outcome measures in these
participants.
Overall assessment of validity
The three included RCTs were classified at high risk of bias (see
table of included studies).
The inter-observer agreement in the overall quality score was not
summarised with the kappa statistic since there was a 100% agree-
ment among the reviewers.
Effects of interventions
A total of 183 (91 treatment, 92 control) out of 210 randomised
participants were considered (27 patients assigned to calcium as-
pirin in the Miller 1961study were excluded from the analysis).
PREVENTION OF DISABILITY WORSENING (PRIMARY
OUTCOME)
(1) at the end of follow up
Data from 2 trials (Miller 1961; Zivadinov 2001) with 136 par-
ticipants, 74% of participants included in the review) were avail-
able on this outcome. Corticosteroid therapy was associated with
a non significant reduction in the risk of being worse at the end
of follow-up (odds ratio [OR] 0.51, 95% confidence interval [CI]
0.26 to 1.02). There was substantial heterogeneity between the
two trials (I2: 78.4%).
(2) at the end of follow up: sensitivity analysis
Since information on patients excluded and lost to follow-up was
unavailable, a worst case scenario was carried out as pre-specified.
Such analysis, performed by considering patients who were ran-
domised to treatment and then excluded as worst outcome events,
did not significantly change the result (number of events in treated
= 30/72; number of events in controls = 37/75; OR 0.74, 95%
CI 0.39 to 1.41) and confirmed the inconsistency across the two
studies (I2: 73.7%).
(3) at one year
Only data from the Zivadinov 2001 study was available, on 81
patients. Corticosteroid therapy was associated with a non signif-
icant reduction in the risk of being worse at 1 year of follow-up
(OR 0.16, 95% CI 0.02 to 1.38).
(4) at one year: sensitivity analysis
Sensitivity analysis of the 88 patients originally randomised did
not change the result (OR 0.86, 95% CI 0.24 to 3.04).
(5) at two years
Only data from the Zivadinov 2001 study was available, on 81
patients. Corticosteroid therapy was associated with a significant
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reduction in the risk of being worse at 2 years of follow-up (OR
0.09, 95% CI 0.02 to 0.42). In absolute terms this means that
330 patients for every 1000 treated (95% CI 170 to 490) avoided
disability progression after two years of treatment.
(6) at two year: sensitivity analysis
Treatment was still associated with a favourable outcome in the
worst case scenario (OR 0.29, 95% CI 0.10 to 0.85).
(7) subgroup analysis
Subgroup analysis was performed since there was substantial het-
erogeneity after efficacy analysis on disability progression at the
end of follow-up. Such analysis should be regarded as a qualitative
rather than quantitative description, since the RCTs considered
were just two (Miller 1961; Zivadinov 2001). Taking into account
the pre-specified issues for subgroup analyses, the two trials did not
differ for quality but they did for type of drug (MP versus pred-
nisolone respectively), route of administration (i. v. versus oral),
regimen (intermittent versus continuous), length of treatment (5
years versus 1 year and a half ), disease course (RR versus variable
course), disability progression definition (objective versus patients’
own assessment in the Miller 1961study) and mean disease dura-
tion before entry into the study (6 years versus 12 years).
I. v. periodic high dose MP was associated with a significant re-
duction in the risk of disability progression at 5 years in RR MS
(OR 0.26, 95% CI 0.10 to 0.66) (Zivadinov 2001), while oral
continuous low dose prednisolone was not associated with any risk
reduction in disability progression at 18 months (OR 1.23, 95%
CI 0.43 to 3.56) (Miller 1961).
In absolute terms, 320 patients for every 1000 treated with pulsed
high dose i. v. MP (95% CI 110 to 520) avoided long term dis-
ability progression according to the Zivadinov study.
PREVENTION OF NEW EXACERBATION (SECONDARY
OUTCOME)
(1) At the end of follow-up
Data from two trials (BPSM 1995; Zivadinov 2001) with 107 par-
ticipants (59%of participants included in the review)was available
on this outcome. Risk of experiencing at least one exacerbation
was not significantly reduced with corticosteroid treatment (OR
0.36; 95% CI 0.10 to 1.25). No substantial heterogeneity across
studies was observed (I2: 0%).
(2) At one year
Data was available from two trials (BPSM 1995; Zivadinov 2001)
with 115 patients. Corticosteroid therapy did non change the risk
of new exacerbations (OR 1.17, 95% CI 0.57 to 2.43).
(3) At two years
Data was available from two trials (BPSM 1995; Zivadinov 2001)
with 107 patients. Corticosteroid therapy did non change the risk
of new exacerbations (OR 1.48, 95% CI 0.61 to 3.59).
(4) Exacerbation-free time
No data was available from the 3 trials included in the review on
this outcome.
ADVERSE EVENTS
(1) Severe adverse events
In the Miller 1961, study adverse events were poorly described
and two patients allocated corticosteroids were withdrawn because
of hypertension. No other severe adverse effects were reported in
either treatment group.
In the Zivadinov 2001, study 2 patients dropped out in the pulsed
i. v. MP arm: in one, i. v. MP was discontinued after the fourth
pulse when the patient developed acute glomerulonephritis; the
second patient was removed from the study after the fifth i. v. MP
pulse because of severe osteoporosis. Twenty-five patients in the i.
v. MP arm and 18 patients in the control arm were followed up 21
months after the study with bone mineral densitometry: a further
patient in the pulsed i. v. MP arm and one in the control arm
developed osteoporosis (Zorzon 2005). There were no fractures
throughout the study.
In the BPSM 1995 study no severe adverse effects were reported
but 7 out of 19 patients (37%) in the pulsed i. v. MP arm versus
3 out of 17 in the control arm (18%) dropped out for unspecified
reasons.
(2) Minor adverse events
Almost all patients treated with i. v. MP in the Zivadinov 2001
study experienced “metallic taste” after the bolus. Insomnia, py-
rosis, anxiety, constipation, acneiform rash, and polyphagia were
frequently reported in both treated and control groups and did
not require treatment.
In the Zivadinov 2001 study the following long term events that
did not require discontinuation of the planned therapy were re-
ported without specifying the treatment group: osteoporosis (2
patients), arterial hypertension (1 patient), and recurrent herpetic
infections (1 patient).
In the BPSM 1995 study careful monitoring of minor adverse
events was also planned but not performed.
In the Miller 1961 study minor adverse events were not reported.
D I S C U S S I O N
Progression of disability
A meta-analysis was not possible for this outcome at one or two
years since data was unavailable. Meta-analysis of two studies for
this outcome at the end of follow up showed a trend towards a
significant effect in favour of steroids, but it is possible that the
substantial heterogeneity between studies diluted the effect of one
of them. Indeed, on the basis of the Zivadinov 2001 study, periodic
high dose i. v. MP significantly prevents progression of long term
disability in patients with RRMS . To quantify the result in terms
of number needed to treat, 3 patients (95% CI 2 to 9) need to
be treated to avoid disability progression in one. This result seems
quite robust as the effects of primary and worst-case meta-analyses
are in the same direction and magnitude. The effect of i. v. MP
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is evident from the second year of treatment and is maintained at
least until the fifth year of treatment.
As opposed to pulsed high dose i. v. MP, continuous low dose
treatment with oral prednisolone did not show any effect neither
on disability progression nor on prevention of new exacerbations.
Different hypotheses could be formulated to explain the difference
in results between the Miller 1961 and Zivadinov 2001 studies:
(a) different drug type (i. v. methylprednisolone in the Zivadinov
2001 study and oral prednisolone in the Miller 1961 study), (b)
the different length of treatment (5 years in the Zivadinov 2001
study and 18 months in the Miller 1961 study), (c) different cu-
mulative dose of steroid (23.04g of i. v. methylprednisolone in the
Zivadinov 2001 study and oral prednisolone equivalent to 5.28g
oral methylprednisolone in the Miller 1961 study, over the first
18 months of both studies), (d) different regimens (pulsed in the
Zivadinov 2001 study and continuous in the Miller 1961 study,
(e) the different type of disease (RR course in the Zivadinov 2001
study and various courses in the Miller 1961 study), (f ) difference
in mean disease duration before entry into the study (6 years in
the Zivadinov 2001 study and 12 years in the Miller 1961 study),
(g) different ethnic background (Italian in the Zivadinov 2001
study and English in the Miller 1961 study), (h) a β type error
(i.e. incapability of identifying a difference that exists) due to low
sample size in the Miller 1961 study, (i) lack of blinding in the
Zivadinov 2001 study, (j) different definition of disability pro-
gression (objective assessment in the Zivadinov 2001 study and
patients’ own assessment in Miller study), (k) a combination of a,
b, c, d, e, f, g, h, i and/or j. A dose-dependent effect might well be
operative since in a trial comparing 2 doses of i. v. MP pulses in
patients with secondary progressive MS, a relative beneficial effect
on time to onset of sustained progression of disability was observed
with the high-dose regimen comparedwith the lowdose (Goodkin
1998a). Although in our analysis the beneficial effect of i. v. MP
was first detected after two years of treatment, in the Zivadinov
2001 study the beneficial effect of pulsed i. v. MP became evident
after 8months of treatment, as shown by the time survival curve to
onset of sustained EDSS score worsening; therefore an effect after
8 months of therapy should have also been visible in the Miller
1961 study, if everything else was equal.
The use of corticosteroid therapy in the control group in the
Zivadinov 2001study could be another cause of heterogeneity.
However, this should have hampered rather than favoured the ef-
fect of corticosteroid in the active treatment group in theZivadinov
2001 study.
Prevention of acute exacerbation
The secondary objective of this review was to evaluate the effect
of treatment on prevention of acute exacerbations. Although one
more RCTcould be included (BPSM 1995) for this analysis, many
patients were lost to followup in this study. I. v.MPdid not protect
against the occurrence of relapses during the period studied.
[the available evidence was extremely weak since many patients
were lost to follow up in this study. Data was not sufficient to
determine the effect of corticosteroid treatment on prevention of
exacerbations; alternatively it could well be that long-term corti-
costeroids do not prevent exacerbations.]
Adverse events
Only one study (Zivadinov 2001) included in this review formally
recorded adverse events following corticosteroid treatment but the
list may be incomplete; consequently the lack of evidence cannot
be construed as paucity of adverse events.
Oral corticosteroids cannot be administered continuously at cu-
mulative doses equivalent to pulsed regimens because of side ef-
fects mostly osteoporosis (Zorzon 2005). This, together with the
negative results from theMiller 1961 study, shift the risk-to-bene-
fit ratio against continuous oral corticosteroid therapy. Compared
to pulsed i. v. MP, there is therefore less evidence favouring further
study in RCTs. As regards periodic high dose i. v. MP, although it
emerged as effective from the present review, routine use in clinical
practice is not yet indicated because the evidence comes from a
single small study that was classified at high risk of bias and was not
open to intention-to-treat analysis. Therefore the evidence cannot
be considered conclusive but rather suggestive of possible efficacy.
Larger RCTs of pulsed i. v. MP are warranted. Due to the reported
lack of difference between oral and i. v. routes of equivalent high
doses of methylprednisolone (Alam 1993), RCTs of pulsed oral
high dose MP are also warranted.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no enough evidence to justify the routine use of long
term corticosteroids treatment for MS patients. This is because
only three trials, all classified at high risk of bias, contributed to
this review.
Implications for research
This review is suggestive of a favourable effect of long term use
of pulsed high dose i. v. MP that could modify the disease course
in RR MS patients. Since it is possible that such an effect is sta-
tistically and clinically significant without severe adverse effects
as compared to other treatments like interferon beta (Rice 2001)
or mitoxantrone (Martinelli 2005), a large and high quality ran-
domised controlled trial is urgently needed to test the efficacy of
pulsed high dose i. v. MP.
No marketing interest may economically sustain the execution of
RCTs on corticosteroids today. Moreover the planning of placebo-
controlled RCTs may be considered unethical when drugs for the
treatment ofMS are available. Therefore, the comparison of pulsed
8Corticosteroids for the long-term treatment in multiple sclerosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
high dose i. v. MP plus a disease modifying drug versus a disease
modifying drug alone could be an option.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
BPSM 1995
Methods C = randomisation by computer.
Double-blind.
Losses to follow-up: 10 (7 assigned MP).
Participants Single centre in Italy;
36 patients with RR clinically definite MS (Poser 1983 criteria); no relapse in the previous 45 days; EDSS
< 5.5.
21 (58%) female
Mean age 35yr.
Interventions Rx: i.v. MP 2 g in saline solution for 12 hours, every 45-60 days, for two years or until relapse
Control: i.v. saline solution at the same schedule
Outcomes Probability of remaining relapse free (primary end point)
Disability reduction after two years
Safety
Notes Prematurely interrupted at 36 out of 72 planned patients for organisational reasons and lack of funding.
Quality C: high risk of bias (concealment of randomisation: present, blinding in outcome evaluation:
present; intention-to-treat analysis: absent [planned but not performed])
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Miller 1961
Methods C = not described.
Double-blind.
Losses to follow-up: 7 (3 assigned Prednisolone, 1 on “dummy” tablets and 3 on calcium aspirin)
Participants Single center in UK;
86 patients with “slowly progressive”, “fluctuant” and “rapidly progressive” MS (diagnostic criteria not
described).
47 (55%) female
Mean age 33yr.
Interventions Rx: 29 patients on oral prednisolone tablets 15 mg/day for 8 months then 10 mg/day for 10 months
Rx: 27 patients on 9 calcium aspirin tablets (54 g)/day
Control: 30 patients on a correspondent number of “dummy” tablets
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Miller 1961 (Continued)
Outcomes Average change in Alexander score
Functional grades at 6 and 18 months
Acute exacerbations
Patients’ own assessment at 18 months
Notes Quality C: high risk of bias (concealment of randomisation: unclear, blinding in outcome evaluation:
present; intention-to-treat analysis: absent)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Zivadinov 2001
Methods C = treatment assignment generated by statistician who had no contact with study subjects.
Single-blind.
Losses to follow up: 7 (4 assigned MP).
No intention-to-treat analysis.
Participants Single center in Italy;
88 patients with RR clinically definite MS (Poser 1983 criteria); without exacerbation or progression and
steroid treatment in the previous 3 months; EDSS < or = 5.5.
60 (68%) female
Mean age 32yr.
Interventions Rx: i.v. MP 1 g/day for 5 days with an oral prednisone taper (day 6 and 7 50 mg, day 8 and 9 25 mg),
every 4 months for 3 years, and every 6 months for the subsequent 2 years
Control: i.v. MP, same dose schedule, only for relapses
Outcomes Primary outcome measure: MRI paremeters (T2 and T1 lesion volume and brain parenchymal volume
changes); secondary outcomes: disability progression and relapses
Notes Quality C: high risk of bias (concealment of randomisation: present, blinding in outcome evaluation:
absent (radiologists blinded but clinical examiners unblinded); intention-to-treat analysis: absent)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
C: concealment of allocation
RR: relapsing remitting
MS: multiple sclerosis
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Rx: Treatment
i.v.: intravenous
MP: methylprednisolone
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beretta 1997 Retrospective study on a series of cases
de Seze 2004 Not randomised (series of patients in post-partum period; historical control group)
Goodkin 1998a No control group with placebo or no treatment (randomised controlled trial of two different dose of bimonthly
i. v. MP pulses)
Pato-Pato 2003 No control group (series of cases). No outcome measures useful for this meta-analysis
Piazza 2000 Uncompleted, confounding randomised trial comparing interferon beta 1b to interferon beta 1b plus MP
Pirko 2004 No control group (series of cases).
Then Bergh 2006 Not randomised single-cross-over study with no outcome measures useful for this meta-analysis
Tourtellotte 1965 Confounding randomised trial comparing oral MP with cyanocobalamin: 30 patients in cyanocobalamin group
had been treated with ACTH during the trial
i.v.: intravenous
MP: methylprednisolone
14Corticosteroids for the long-term treatment in multiple sclerosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroids versus placebo or open control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disability progression at end of
follow-up
2 136 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.26, 1.02]
1.1 Intermittent corticosteroid
treatment
1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.10, 0.66]
1.2 Continuous corticosteroid
treatment
1 55 Odds Ratio (M-H, Fixed, 95% CI) 1.23 [0.43, 3.56]
2 Disability progression at end of
follow-up: sensitivity analysis
2 147 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.39, 1.41]
2.1 Intermittent corticosteroid
treatment
1 88 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.18, 1.00]
2.2 Continuous corticosteroid
treatment
1 59 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.58, 4.50]
3 Disability progression at year 1 1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.38]
4 Disability progression at year 1:
sensitivity analysis
1 88 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.24, 3.04]
5 Disability progression at year 2 1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.02, 0.42]
6 Disability progression at year 2:
sensitivity analysis
1 88 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.10, 0.85]
7 New exacerbations at end of
follow-up
2 107 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.10, 1.25]
8 New exacerbations at year 1 2 115 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.57, 2.43]
9 New exacerbations at year 2 2 107 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.61, 3.59]
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Analysis 1.1. Comparison 1 Corticosteroids versus placebo or open control, Outcome 1 Disability
progression at end of follow-up.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 1 Disability progression at end of follow-up
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent corticosteroid treatment
Zivadinov 2001 10/39 24/42 73.7 % 0.26 [ 0.10, 0.66 ]
Subtotal (95% CI) 39 42 73.7 % 0.26 [ 0.10, 0.66 ]
Total events: 10 (Treated), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
2 Continuous corticosteroid treatment
Miller 1961 13/26 13/29 26.3 % 1.23 [ 0.43, 3.56 ]
Subtotal (95% CI) 26 29 26.3 % 1.23 [ 0.43, 3.56 ]
Total events: 13 (Treated), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 65 71 100.0 % 0.51 [ 0.26, 1.02 ]
Total events: 23 (Treated), 37 (Control)
Heterogeneity: Chi2 = 4.64, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.92 (P = 0.055)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Corticosteroids versus placebo or open control, Outcome 2 Disability
progression at end of follow-up: sensitivity analysis.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 2 Disability progression at end of follow-up: sensitivity analysis
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intermittent corticosteroid treatment
Zivadinov 2001 14/43 24/45 73.4 % 0.42 [ 0.18, 1.00 ]
Subtotal (95% CI) 43 45 73.4 % 0.42 [ 0.18, 1.00 ]
Total events: 14 (Treated), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
2 Continuous corticosteroid treatment
Miller 1961 16/29 13/30 26.6 % 1.61 [ 0.58, 4.50 ]
Subtotal (95% CI) 29 30 26.6 % 1.61 [ 0.58, 4.50 ]
Total events: 16 (Treated), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 72 75 100.0 % 0.74 [ 0.39, 1.41 ]
Total events: 30 (Treated), 37 (Control)
Heterogeneity: Chi2 = 3.80, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.92 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
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Analysis 1.3. Comparison 1 Corticosteroids versus placebo or open control, Outcome 3 Disability
progression at year 1.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 3 Disability progression at year 1
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zivadinov 2001 1/39 6/42 100.0 % 0.16 [ 0.02, 1.38 ]
Total (95% CI) 39 42 100.0 % 0.16 [ 0.02, 1.38 ]
Total events: 1 (Treated), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
Analysis 1.4. Comparison 1 Corticosteroids versus placebo or open control, Outcome 4 Disability
progression at year 1: sensitivity analysis.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 4 Disability progression at year 1: sensitivity analysis
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zivadinov 2001 5/43 6/45 100.0 % 0.86 [ 0.24, 3.04 ]
Total (95% CI) 43 45 100.0 % 0.86 [ 0.24, 3.04 ]
Total events: 5 (Treated), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
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Analysis 1.5. Comparison 1 Corticosteroids versus placebo or open control, Outcome 5 Disability
progression at year 2.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 5 Disability progression at year 2
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zivadinov 2001 2/39 16/42 100.0 % 0.09 [ 0.02, 0.42 ]
Total (95% CI) 39 42 100.0 % 0.09 [ 0.02, 0.42 ]
Total events: 2 (Treated), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
0.01 0.1 1 10 100
Favours treatment Favours control
Analysis 1.6. Comparison 1 Corticosteroids versus placebo or open control, Outcome 6 Disability
progression at year 2: sensitivity analysis.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 6 Disability progression at year 2: sensitivity analysis
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zivadinov 2001 6/43 16/45 100.0 % 0.29 [ 0.10, 0.85 ]
Total (95% CI) 43 45 100.0 % 0.29 [ 0.10, 0.85 ]
Total events: 6 (Treated), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
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Analysis 1.7. Comparison 1 Corticosteroids versus placebo or open control, Outcome 7 New exacerbations
at end of follow-up.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 7 New exacerbations at end of follow-up
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BPSM 1995 11/12 13/14 11.5 % 0.85 [ 0.05, 15.16 ]
Zivadinov 2001 31/39 39/42 88.5 % 0.30 [ 0.07, 1.22 ]
Total (95% CI) 51 56 100.0 % 0.36 [ 0.10, 1.25 ]
Total events: 42 (Treated), 52 (Control)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
Analysis 1.8. Comparison 1 Corticosteroids versus placebo or open control, Outcome 8 New exacerbations
at year 1.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 8 New exacerbations at year 1
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BPSM 1995 9/18 11/16 43.5 % 0.45 [ 0.11, 1.85 ]
Zivadinov 2001 22/39 18/42 56.5 % 1.73 [ 0.72, 4.16 ]
Total (95% CI) 57 58 100.0 % 1.17 [ 0.57, 2.43 ]
Total events: 31 (Treated), 29 (Control)
Heterogeneity: Chi2 = 2.49, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.43 (P = 0.67)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
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Analysis 1.9. Comparison 1 Corticosteroids versus placebo or open control, Outcome 9 New exacerbations
at year 2.
Review: Corticosteroids for the long-term treatment in multiple sclerosis
Comparison: 1 Corticosteroids versus placebo or open control
Outcome: 9 New exacerbations at year 2
Study or subgroup Treated Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
BPSM 1995 11/12 13/14 12.4 % 0.85 [ 0.05, 15.16 ]
Zivadinov 2001 28/39 26/42 87.6 % 1.57 [ 0.61, 3.99 ]
Total (95% CI) 51 56 100.0 % 1.48 [ 0.61, 3.59 ]
Total events: 39 (Treated), 39 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
0.1 0.2 0.5 1 2 5 10
More in controls More in cases
A D D I T I O N A L T A B L E S
Table 1. Form for quality assessment
Study: Concealment Blinding Int-to-treat
Concealment of randomisation Blinding in outcome evaluation Intention-to-treat analysis
present YES/NO YES/NO YES/NO
absent YES/NO YES/NO YES/NO
unclear YES/NO YES/NO YES/NO
Table 2. Data Collection Form
Study Treated N=? Control N=?
Droppedout/excluded after randomisation n=? n=?
Pts who progressed* at 1 yr n=? n=?
Pts who progressed* at 2 yrs n=? n=?
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Table 2. Data Collection Form (Continued)
Pts who progressed* at end of follow-up n=? n=?
Pts experiencing at least one exacerbation
at 1 yr
n=? n=?
Pts experiencing at least one exacerbation
at 2 yrs
n=? n=?
Pts experiencing at least one exacerbation
at end of follow-up
n=? n=?
Pts with severe side effects (please specify) n=? n=?
Other side effects (please specify) n=? n=?
* Progression is defined as a persistent
worsening of at least one point in EDSS,
recorded whilst not in relapse. Other def-
initions of progression could be accepted,
including a persistent half-point increase
starting from EDSS score 5.5
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1MeSH descriptor Multiple Sclerosis explode all trees
#2MeSH descriptor Demyelinating Diseases, this term only
#3MeSH descriptor Myelitis, Transverse, this term only
#4MeSH descriptor Optic Neuritis explode all trees
#5MeSH descriptor Encephalomyelitis, Acute Disseminated, this term only
#6(multiple sclerosis)
#7(demyelinating disease*)
#8(transverse myelitis)
#9(neuromyelitis optica)
#10(optic neuritis)
#11(encephalomyelitis acute disseminated)
#12(devic)
#13(#1 OR #1 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14MeSH descriptor Adrenal Cortex Hormones explode all trees
#15MeSH descriptor Steroids explode all trees
#16MeSH descriptor Methylprednisolone explode all trees
#17MeSH descriptor Prednisolone, this term only
#18MeSH descriptor Dexamethasone explode all trees
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#19(corticosteroids)
#20(steroids)
#21(methylprednisolone)
#22(prednisone)
#23(prednisolone)
#24(dexamethasone)
#25(acth)
#26MP
#27corticotrophic AND hormone
#28(#14 OR 16 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29(#28 AND #13)
Appendix 2. MEDLINE (PubMed) search strategy
((((“Multiple Sclerosis”[mh]) OR (“Myelitis, Transverse”[mh:noexp]) OR (“Demyelinating Diseases”[mh:noexp]) OR (“En-
cephalomyelitis, Acute Disseminated”[mh:noexp]) OR (“Optic Neuritis”[mh])) OR (((“multiple sclerosis”) OR (“neuromyelitis op-
tica”) OR (“transverse myelitis”) OR (encephalomyelitis) OR (devic) OR (“optic neuritis”)) OR (“demyelinating disease*”) OR
(“acute disseminated encephalomyelitis”))) AND (((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (random-
ized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT ((animals[mh])
NOT ((animals[mh]) AND (human[mh]))))) AND (((corticosteroids) OR (steroids) OR (methylprednisolone) OR (MP) OR (pred-
nisone) OR (prednisolone) OR (dexamethasone) OR (ACTH) OR (corticotrophic AND hormone)) OR ((“Adrenal Cortex Hor-
mones”[mh]) OR (“Steroids”[mh]) OR (“Methylprednisolone”[mh]) OR (“Prednisone”[mh:noexp]) OR (“Dexamethasone”[mh]) OR
(“prednisolone”[mh:noexp])))
Appendix 3. EMBASE (EMBASE.com) search strategy
(((’encephalomyelitis’/exp)OR (’demyelinating disease’/exp)OR (’multiple sclerosis’/exp)OR (’myelooptic neuropathy’/exp)OR (’mul-
tiple sclerosis’:ti,ab) OR (’neuromyelitis optica’:ab,ti) OR (encephalomyelitis:ab,ti) OR (devic:ti,ab)) AND ((’crossover procedure’/exp)
OR (’double blind procedure’/exp) OR (’single blind procedure’/exp) OR (’randomized controlled trial’/exp) OR (random*:ab,ti) OR
(factorial*:ab,ti) OR (crossover:ab,ti) OR (cross:ab,ti AND over:ab,ti) OR (placebo:ab,ti) OR (’double blind’:ab,ti) OR (’single blind’:
ab,ti) OR (assign*:ab,ti) OR (allocat*:ab,ti) OR (volunteer*:ab,ti))) AND ((’corticosteroid’/exp) OR (’steroid’/exp AND [embase]/lim)
OR (’methylprednisolone’/exp) OR (’dexamethasone’/exp) OR (’corticotropin’/exp) OR (corticosteroid*:ab,ti OR steroid*:ab,ti OR
methylprednisolone:ab,ti OR prednisolone:ab,ti OR dexamethasone:ab,ti OR corticotropin:ab,ti)) AND [humans]/lim AND [em-
base]/lim
WH A T ’ S N E W
Last assessed as up-to-date: 2 August 2007.
Date Event Description
22 August 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
Dr Alfonso Ciccone conceived and wrote most part of this review that was checked and discussed with the other authors who approved
the final version. Dr Sandro Beretta, Dr. Fabio Brusaferri, Dr. Ian Galea, Dr. Alessandra Protti and Dr. Chiara Spreafico selected the
trials, extracted the data and assessed the quality of the trials. Dr. Fabio Brusaferri checked all references pertinent to this review already
used in two systematic reviews on corticosteroids for multiple sclerosis whose he was one of the authors. Dr. Ian Galea contacted one
manufacturer of corticosteroids and active researchers known to have an interest in the use of steroids in MS in order to identify any
unpublished data and wrote the “Synopsis”. Dr. Sandro Beretta shared data of an unpublished trial that was checked with Dr. Chiara
Spreafico. Dr Alfonso Ciccone performed the analyses and Dr. Sandro Beretta assisted in statistical analysis. Dr. Chiara Spreafico and
Dr. Alessandra Protti prepared the abstract.
D E C L A R A T I O N S O F I N T E R E S T
Two reviewers (Alfonso Ciccone and Sandro Beretta) had a leading role in a randomised controlled trial on pulsed high dose intravenous
methylprednisolone for relapsing remittingmultiple sclerosis, included in the review andquoted asBPSM 1995 (Boli Steroidei Preventivi
nella Sclerosi Multipla).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Long-Term Care; Adrenal Cortex Hormones [adverse effects; ∗therapeutic use]; Disease Progression; Methylprednisolone [adverse
effects; therapeutic use]; Multiple Sclerosis [∗drug therapy]; Prednisolone [adverse effects; therapeutic use]; Randomized Controlled
Trials as Topic
MeSH check words
Humans
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